GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Total Current Assets

EBACU (European Biotech Acquisition) Total Current Assets : $0.36 Mil (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. European Biotech Acquisition's total current assets for the quarter that ended in Dec. 2022 was $0.36 Mil.

European Biotech Acquisition Total Current Assets Historical Data

The historical data trend for European Biotech Acquisition's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Biotech Acquisition Total Current Assets Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
Total Current Assets
0.92 0.36

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Current Assets Get a 7-Day Free Trial 0.92 0.95 0.48 0.39 0.36

European Biotech Acquisition Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

European Biotech Acquisition's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.308+0+0+0.049
=0.36

European Biotech Acquisition's Total Current Assets for the quarter that ended in Dec. 2022 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.308+0+0+0.049
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

European Biotech Acquisition  (NAS:EBACU) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

European Biotech Acquisition's Liquidation Value for the quarter that ended in Dec. 2022 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.308-8.548+0.75 * 0+0.5 * 0
=-8.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition Total Current Assets Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

European Biotech Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Total Current Assets
Comparable Companies
CNTQ LION MEOA SCMA LATG NBST CCTS FRBN NMMC DMAQ GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
EPFL Innovation Park Building, Lausanne, CHE, 1015
Website
https://www.lspvc.com
European Biotech Acquisition Corp is a blank check company.
Executives
Mohammad Sohail Fazeli director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen director RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo officer: Chief Executive Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas officer: Chief Financial Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno director JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV